Antivax and cancer quackery go together, unfortunately. Here, Orac describes yet another example of this, as the (Not-So)-Thinking Moms promote a fundraiser to pay for quackery, including IonCleanse footpaths, for a young woman with cancer.
This is the conclusion of my series on Clínica 0-19, the cancer clinic where Drs. Alberto Siller and Alberto Garcia see patients with DIPG, a deadly brain tumor, whom they treat at Hospital Angeles in Monterrey Mexico with an unproven combination of intra-arterial chemotherapy with up to 11 drugs and a poorly defined dendritic cell immunotherapy. Some people have asked me: What’s the harm? In this concluding post, I attempt to answer that question.
Earlier this week, I discussed Clínica 0-19, a clinic “making DIPG history in Monterrey” whose doctors claim to be able to successfully treat the deadly brainstem cancer DIPG using intra-arterial chemotherapy and immunotherapy. This week, I discuss what I’ve learned since last week, specifically a lot more about just what it is that these doctors do, why it is scientifically dubious and unproven, and why I am becoming even more harsh in my assessment of this clinic, which shows every indication of being a predatory clinic selling an unproven treatment for a very high price.
Drs. Alberto Siller and Alberto Garcia run Clínica 0-19 in Monterrey, Mexico, which has become a magnet for patients with diffuse intrinsic pontine glioma (DIPG), a deadly brain cancer. Unfortunately, their treatment is an unproven combination of 11 chemotherapy drugs injected into an artery feeding the brainstem, plus an unknown and unproven “immunotherapy.” Of course it all costs $300,000 or more for a complete course of treatment, and the good doctors are “too busy to do clinical trials” or even publish their survival and recurrence statistics, despite having used this protocol for 20 years. I say: If it quacks like a duck…
Alternative medicine mavens like to promote a stereotype of cancer doctors as practically slavering to poison patients with chemotherapy. The TAILORx trial and its results would beg to differ.